MorphoSys to Present at Five Upcoming Conferences
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Present at Five Upcoming Conferences
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present
at the following conferences:
ASCO (American Society of Clinical Oncology) Annual Meeting 2015
Date: May 29, 2015 - June 2, 2015
Venue: Chicago, IL, USA
Jefferies 2015 Global Health Care Conference
Date: June 3, 2015, 10:30am EDT (4:30pm CEST, 3:30pm BST)
Venue: New York, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,
Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
Goldman Sachs 36th Annual Global Healthcare Conference
Date: June 10, 2015, 2:00pm PDT (11:00pm CEST, 10:00pm BST)
Venue: Rancho Palos Verdes, CA, USA
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
dbAccess German, Swiss & Austrian Conference
Date: June 17, 2015, 5:15pm CEST (4:15pm BST, 11:15am EDT)
Venue: Berlin, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
J.P. Morgan Cazenove European Healthcare Conference
Date: June 25, 2015
Venue: London, UK
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
A PDF version of all presentations will be provided at www.morphosys.com.
The link to webcasts will be filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 90 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Jessica Rush
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1924488/690340.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1924488]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 29.05.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 396801
Anzahl Zeichen: 4755
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 309 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Present at Five Upcoming Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).





